AB0557 ACHIEVING TREATMENT TARGETS IN PSORIATIC ARTHRITIS WITH APREMILAST IN CANADIAN PRACTICE: REAL WORLD RESULTS FROM APPRAISE

Background: Real-world evidence on achieving treatment targets with apremilast (APR) in patients (pts) PsA is limited. In the phase 3 PALACE trials, pts reached remission (REM)/low disease activity (LDA) at 52 wks most frequently when early APR was initiated and were moderate activity, as measured by Clinical Disease Activity Index for (cDAPSA) score. APPRAISE, we assessed effectiveness/tolerability routine clinical practice Canada. Objectives: This interim efficacy analysis focused available data effectiveness measuring rate of cDAPSA REM or LDA 12 mos Pt Acceptable Symptom Status (PASS) results. Methods: The prospective, multicenter, observational APPRAISE study adults active care enrolled from July 2018-March 2020. Pts followed initiation to mos, visits suggested every 4 mos. primary endpoint least (cDAPSA <14) Pt-reported outcome measures assessed. Data reported are observed continuing treatment. Results: total, 101 APPRAISE. Mean age yrs; 56% women. (SD) duration baseline (BL) 6 (8) yrs. Oligoarticular (≤4 joint involvement) common (41%), polyarticular (35%). Most (92%) received prior conventional DMARDs 17% biologic therapy; concomitant MTX 41% BL. By 41/101 discontinued, 35 follow-up (4 mos: n=92; 8 n=61), 25 have yet reach majority discontinuations due lack/loss AEs occurred within 4-8 primarily GI related proportion continued REM/LDA increased significantly over time (Figure 1). Significant reductions seen swollen/tender counts plaque psoriasis, reduced mean body surface area −4% (9%) (Table Prevalence dactylitis/enthesitis BL, 4, 8, 17%/33%, 9%/24%, 5%/19%, 0%/21%, respectively. Pain assessment (VAS) improved time. PASS (BL: 27%; 65%) COVID restrictions impacted in-office visits, necessitating reliance virtual visits. Conclusion: receiving regular intervals revealed a greater number (66%) who completed 12-mo achieved LDA, A (65%) satisfaction their state, PASS. No new safety signals observed. Table 1. Change Parameters Pt-Reported Outcomes From BL Mos Outcome Measure*, (SD ) (n = 92 61 Disease/Clinical Tender count (0-68) 7.5 (6.7) −2.5 (6.3)* −3.9 (5.2)* −2.2 (6.4) Swollen (0-66) 5.4 (5.4) −3.0 (4.5)* −3.1 (4.3)* (4.4)* PhGA 42.9 (18.8) −19.0 (24.6)* −24.2 (24.2)* −21.2 (26.3)* Body area, % 3.1 (6.1) (6.0)* −2.7 (7.5)* −4.2 (9.1)* 22.2 (13.3) −7.9 (12.1)* −10.1 (13.5)* −6.9 (12.0)* PtGA, mm 50.0 (24.6) −10.2 (27.5)* −9.1 (31.9)* −3.6 (39.7) Pain, 48.3 (25.3) −9.5 (26.2)* −12.2 (28.7)* −7.3 (26.0) HAQ-DI 0.9 (0.7) −0.13 (0.5)* −0.15 (0.6) −0.1 *Denotes significant change ( P <0.05) paired-sample t -tests; note that may be than value improvements large magnitude, relatively elevated values, samples lower n’s. Health Assessment Questionnaire-Disability Index; Physician’s Global Assessment; PtGA Patient’s Assessment. Acknowledgements: funded Celgene Amgen Inc. Writing support provided Kristin Carlin, RPh, MBA, Peloton Advantage, LLC, an OPEN company. Disclosure Interests: Vinod Chandran Consultant of: AbbVie, Amgen, BMS, Corporation, Eli Lilly, Janssen, Novartis, Pfizer, UCB, Grant/research from: Louis Bessette Merck, Sanofi, Carter Thorne Speakers bureau: Medexus/Medac, Sandoz, Centocor, Maqbool Sheriff Proton Rahman Celgene, Dafna D Gladman Galapagos, Gilead, Sabeen Anwar Inc., Jennifer Jelley Employee Canada Anne-Julie Gaudreau Manprit Chohan John S. Sampalis JSS Medical Research.